3D Midbrain Organoids Through Sequential Neural Patterning
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for generating human brain organoids, particularly midbrain organoids, are limited to two-dimensional cultures that fail to recapitulate the complexity and functionality of the developing nervous system, hindering research on brain disorders and the development of mature brain structures.
Innovation Solution
A method involving the culture of pluripotent stem cells to derive neuronal lineage embryoid bodies, followed by embedding midbrain regionalized tissues in an extracellular matrix to generate midbrain-like organoids, using specific culture media comprising TGF-β inhibitors, SMAD2/3 inhibitors, WNT-signalling activators, hedgehog signalling proteins, fibroblast growth factors, and neurotrophic factors to promote the development of functional midbrain structures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional two-dimensional culture methods are used to generate brain organoids, then the process is simple and easy to maintain, but the organoids fail to recapitulate the complexity and functionality of the developing nervous system
Solution Approach 1:
The patent transitions from two-dimensional culture methods to three-dimensional organoid culture systems. This dimensional change enables the formation of complex neural structures with proper cytoarchitecture, including cortical layers and midbrain regions, while maintaining ease of culture through standardized protocols using extracellular matrix substrates and defined culture conditions.
2Reliability
If three-dimensional organoid culture systems are implemented to recapitulate nervous system complexity, then functional maturity and structural accuracy are improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent employs systematic parameter changes in the culture system, including optimizing extracellular matrix composition, controlling growth factor concentrations (such as FGF8, SHH), regulating oxygen levels, and adjusting culture duration. These parameter optimizations enable reliable generation of mature midbrain organoids with dopaminergic neurons while managing culture system complexity through standardized protocols.
3Productivity
If existing differentiation protocols are used, then neuronal cell generation is achieved, but the specific midbrain structures and dopaminergic neuron functionality are not properly developed
Solution Approach 1:
The patent applies local quality principles by creating spatially distinct regions within the organoids that mimic the natural organization of the midbrain. This includes establishing ventral midbrain regions with dopaminergic neurons, dorsal regions with different neuronal types, and proper laminar structures. The culture medium is locally optimized with region-specific growth factors and signaling molecules to achieve anatomically precise midbrain structures.
Solution Approach 2:
The protocol incorporates preliminary actions by first establishing neural progenitor zones with specific transcription factor expression (such as LMX1A, FOXA2) before inducing dopaminergic differentiation. Growth factors like FGF8 and SHH are applied in predetermined sequences to pre-pattern the tissue, ensuring proper midbrain identity and regional specification before final neuronal maturation occurs.
Data Source
AI summary
The present disclosure provides a method of deriving and maintaining a midbrain-like organoid in culture, comprising (a) culturing pluripotent stem cells to obtain neuronal lineage embryoid bodies; (b) culturing the neuronal lineage embryoid bodies from (a) to obtain midbrain regionalized tissues; (c) embedding and culturing the midbrain regionalized tissues from (b) in an extracellular matrix to obtain neuroepithelial tissues; and (c) culturing the neuroepithelial tissues from (c) to obtain a midbrain-like organoid. Also disclosed herein are culture media suitable for deriving and maintaining neuronal lineage embryoid bodies comprising (a) TGF-β Inhibitor and/or SMAD2/3 inhibitors; and (b) WNT-signaling activator; culture media suitable for deriving and maintaining midbrain regionalized tissues comprising (a) TGF-β Inhibitor and/or SMAD2/3 inhibitors; (b) WNT-signaling activator; (c) hedgehog signaling protein; and (d) fibroblast growth factor; culture media suitable for deriving and maintaining neuroepithelial tissues comprising (a) hedgehog signaling protein; and (b) fibroblast growth factor and culture media suitable for deriving and maintaining a midbrain-like organoid comprising (a) neurotrophin factor; (b) ascorbic acid; and (c) activator of cAMP-dependent pathway.